This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Effect of resveratrol administration on ovarian morphology, determined by transvaginal ultrasound in patients with PCOS
Asieh Mansour
tums
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4543-8757
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
High rate of anovulation in PCOS is associated with lack of development a dominant follicle. Intake of resveratrol has been associated with improved ovarian morphology in vitro and in animal PCOS model, but this finding has not been confirmed in randomized trials.
Methods
We randomly assigned 41 patients with PCOS, but without evidence of major medical disorders and who was not taking confounding medications including insulin sensitizers and steroids to received 1000 mg capsules containing resveratrol or matching placebo daily for up to 3 months. Transvaginal ultrasound examination was used to evaluate ovarian morphology.
Results
Resveratrol therapy, as compared with placebo, was associated with significantly higher rate of improvement in ovarian morphology (resveratrol group: 5 no polycystic ovarian morphology (PCOM), 8 bilateral and 6 unilateral and placebo group: 10 bilateral and 7 unilateral, (p= 0.02)). Women who received resveratrol had more dominant follicle than who received placebo with a significant reduction in ovarian volume (p<0.05). However, the number of antral follicles per ovary (FNPO) and stromal area were not significantly altered (P>0.05).
Conclusions
This study offered the novel therapeutic approach of resveratrol administration for PCOS women.
Keywords
Resveratrol, Ovarian morphology, Transvaginal Ultrasound, PCOS, Polycystic ovary syndrome
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 19 Dec, 2019
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Effect of resveratrol administration on ovarian morphology, determined by transvaginal ultrasound in patients with PCOS
Asieh Mansour
tums
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4543-8757
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 19 Dec, 2019
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
High rate of anovulation in PCOS is associated with lack of development a dominant follicle. Intake of resveratrol has been associated with improved ovarian morphology in vitro and in animal PCOS model, but this finding has not been confirmed in randomized trials.
Methods
We randomly assigned 41 patients with PCOS, but without evidence of major medical disorders and who was not taking confounding medications including insulin sensitizers and steroids to received 1000 mg capsules containing resveratrol or matching placebo daily for up to 3 months. Transvaginal ultrasound examination was used to evaluate ovarian morphology.
Results
Resveratrol therapy, as compared with placebo, was associated with significantly higher rate of improvement in ovarian morphology (resveratrol group: 5 no polycystic ovarian morphology (PCOM), 8 bilateral and 6 unilateral and placebo group: 10 bilateral and 7 unilateral, (p= 0.02)). Women who received resveratrol had more dominant follicle than who received placebo with a significant reduction in ovarian volume (p<0.05). However, the number of antral follicles per ovary (FNPO) and stromal area were not significantly altered (P>0.05).
Conclusions
This study offered the novel therapeutic approach of resveratrol administration for PCOS women.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7